LEADER 03034oam  2200781   450 
001 9910715226403321
005 20220614140749.0
035   $a(CKB)5470000002509763
035   $a(OCoLC)1233296597$z(OCoLC)1237322777
035   $a(OCoLC)995470000002509763
035   $a(EXLCZ)995470000002509763
100   $a20210129d2021      ua             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aCOVID-19: critical vaccine distribution, supply chain, program integrity, and other challenges require focused federal attention $ereport to congressional committees
210  1$a[Washington, D.C.] :$cUnited States Government Accountability Office,$d2021.
215   $a1 online resource (vii, 333 pages) $ccolor illustrations
300   $a"January 2021."
300   $a"GAO-21-265."
320   $aIncludes bibliographical references.
517   $aCOVID-19
606   $aCOVID-19 (Disease)$xVaccination$zUnited States$xPlanning
606   $aCOVID-19 (Disease)$xEconomic aspects$zUnited States
606   $aCOVID-19 (Disease)$xDiagnosis$zUnited States
606   $aCOVID-19 (Disease)$zUnited States$xPrevention
606   $aCOVID-19 (Disease)$xTreatment$zUnited States
606   $aVaccines industry$xGovernment policy$zUnited States
606   $aVaccines$xDevelopment$zUnited States
606   $aPublic health administration$zUnited States
606   $aCOVID-19 (Disease)$xDiagnosis$2fast
606   $aCOVID-19 (Disease)$xEconomic aspects$2fast
606   $aCOVID-19 (Disease)$xPrevention$2fast
606   $aCOVID-19 (Disease)$xTreatment$2fast
606   $aExpenditures, Public$2fast
606   $aPublic health administration$2fast
606   $aVaccines industry$xGovernment policy$2fast
607   $aUnited States$xAppropriations and expenditures
607   $aUnited States$2fast
615  0$aCOVID-19 (Disease)$xVaccination$xPlanning.
615  0$aCOVID-19 (Disease)$xEconomic aspects
615  0$aCOVID-19 (Disease)$xDiagnosis
615  0$aCOVID-19 (Disease)$xPrevention.
615  0$aCOVID-19 (Disease)$xTreatment
615  0$aVaccines industry$xGovernment policy
615  0$aVaccines$xDevelopment
615  0$aPublic health administration
615  7$aCOVID-19 (Disease)$xDiagnosis.
615  7$aCOVID-19 (Disease)$xEconomic aspects.
615  7$aCOVID-19 (Disease)$xPrevention.
615  7$aCOVID-19 (Disease)$xTreatment.
615  7$aExpenditures, Public.
615  7$aPublic health administration.
615  7$aVaccines industry$xGovernment policy.
801  0$bGPO
801  1$bGPO
801  2$bOCLCO
801  2$bOCLCF
801  2$bOCLCO
801  2$bOCLCQ
801  2$bS2H
801  2$bGPO
906   $aBOOK
912   $a9910715226403321
996   $aCOVID-19: critical vaccine distribution, supply chain, program integrity, and other challenges require focused federal attention$93437581
997   $aUNINA